Floatz logo

INTERLEUKIN-21

Leukemia, B-cell

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Leukemia, B-cell cohort.

Asset / SponsorPhaseRating
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Cyclophosphamide
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Dasatinib
Nanfang Hospital, Southern Medical University
Phase 2/3B
Tucidinostat
Nanfang Hospital, Southern Medical University
Phase 2/3B

View all 16 →

Same molecule, other indications

INTERLEUKIN-21 is also rated in:

Lymphoma, HodgkinsDormant
CC
Indicative ·
47 / 100
View asset →
Lymphoma, Non-hodgkinsDormant
CC
Indicative ·
47 / 100
View asset →
Lymphoma, B-CellDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →